| Not Yet Recruiting | Evaluation of Skin Tests in Biotherapy Allergies NCT06971848 | University Hospital, Angers | N/A |
| Not Yet Recruiting | FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers NCT07478523 | University Hospital, Bordeaux | Phase 2 |
| Not Yet Recruiting | TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary T NCT07454486 | Aarhus University Hospital | — |
| Not Yet Recruiting | The Efficacy and Safety of Pucotenlimab (PD-1) Combined With Becotatugvedotin (EGFR-ADC) in Advanced Cholangio NCT07514533 | Sir Run Run Shaw Hospital | Phase 2 |
| Recruiting | Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies NCT07486713 | Rigel Pharmaceuticals | Phase 4 |
| Not Yet Recruiting | Hepatobiliary and Pancreatic Tumor Biobank NCT07344116 | Second Affiliated Hospital, School of Medicine, Zhejiang University | — |
| Not Yet Recruiting | Adjuvant Chemotherapy for BTC Based on 3D-PTA NCT07296666 | Fudan University | Phase 2 |
| Recruiting | Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer NCT07146646 | Case Comprehensive Cancer Center | Phase 2 |
| Recruiting | Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangioca NCT07260175 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 2 |
| Recruiting | PULSAR Combined With Immunotherapy and Chemotherapy NCT07291947 | Wang Xin | Phase 1 / Phase 2 |
| Not Yet Recruiting | Validation of the Proteomic Profiling as a Diagnostic Test for Extra-hepatic Cholangiocarcinoma NCT06780553 | University Hospital, Bordeaux | — |
| Recruiting | Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia NCT07359586 | Zhejiang University | — |
| Recruiting | A Study of LY4337713 in Participants With FAP-Positive Solid Tumors NCT07213791 | Eli Lilly and Company | Phase 1 |
| Not Yet Recruiting | In-Depth Characterisation of Biliary Strictures and Hepato-Pancreato-Biliary Focal Lesions for Development of NCT07206355 | University of Nottingham | — |
| Recruiting | Mechanistic Study on the Protective and Regenerative Effects of Spirulina in Hepatectomy-Related Liver Injury NCT07263217 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Not Yet Recruiting | Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma (POELH-III) NCT07161869 | Erasmus Medical Center | — |
| Recruiting | Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas NCT07155525 | Minia University | Phase 3 |
| Withdrawn | A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With NCT06690281 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection NCT06503146 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | A Study of GV20-0251 in Advanced or Refractory Solid Tumors NCT07106827 | West China Hospital | Phase 1 |
| Not Yet Recruiting | Spanish Registry of Direct Cholangiopancreatoscopy by Single Operator NCT07064447 | Germans Trias i Pujol Hospital | — |
| Recruiting | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematolog NCT07118176 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Recruiting | HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receivin NCT06899152 | Montefiore Medical Center | N/A |
| Recruiting | Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Ad NCT07105852 | Sir Run Run Shaw Hospital | Phase 2 |
| Not Yet Recruiting | Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable H NCT07030140 | Jinbo Yue | Phase 2 |
| Not Yet Recruiting | Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma NCT06903273 | National Cheng-Kung University Hospital | Phase 2 |
| Recruiting | Streamlining Radioembolization for CCC and Metastatic Liver Cancer NCT07043387 | Seoul National University Hospital | — |
| Recruiting | Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer NCT07025174 | First Affiliated Hospital of Zhejiang University | Phase 2 |
| Recruiting | On-treatment Surveillance of Tumor Evolution and Response to Systemic Treatment in Bile Duct and Liver Cancer NCT06877637 | Region Skane | — |
| Recruiting | Diagnostic Approach for Cholangiocarcinoma Using Liquid Bile Biopsy NCT06416397 | University Hospital, Bordeaux | — |
| Recruiting | Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid NCT06910670 | Washington University School of Medicine | N/A |
| Recruiting | The Dragon PLC Trial (DRAGON-PLC) NCT06914648 | Maastricht University | N/A |
| Recruiting | A Study of MGC028 in Participants With Advanced Solid Tumors NCT06723236 | MacroGenics | Phase 1 |
| Recruiting | A Simple Breath Test to Detect Liver Cancer and Monitor Liver Conditions NCT06864195 | Imperial College London | — |
| Not Yet Recruiting | Cell-Surface Plectin in the Diagnosis of Cholangiocarcinoma from ERCP-directed Biliary Samples NCT06651346 | University of Virginia | — |
| Active Not Recruiting | A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors NCT06777316 | Cogent Biosciences, Inc. | Phase 1 / Phase 2 |
| Recruiting | Trop2-targeted immunoPET Imaging of Solid Tumors NCT06851663 | RenJi Hospital | Phase 2 / Phase 3 |
| Active Not Recruiting | The Future Management of Patients With Neoplasms of the Gastro-intestinal Tract NCT06728358 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Recruiting | The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma NCT06355427 | Mara Veenstra, MD | Phase 2 / Phase 3 |
| Not Yet Recruiting | Evaluation of Combined Modality Protons and Hepatic Transplantation for Hilar Cholangiocarcinoma NCT06434493 | The Christie NHS Foundation Trust | N/A |
| Withdrawn | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs NCT04985357 | Travera Inc | — |
| Not Yet Recruiting | A Novel Serological Risk Model for Early Non-invasive Diagnosis of Cholangiocarcinoma NCT06658587 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Not Yet Recruiting | Spanish Registry of Quality Indicators and Adverse Events of Endoscopic Retrograde Cholangiopancreatography NCT06670547 | Germans Trias i Pujol Hospital | — |
| Recruiting | Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Trac NCT06546969 | University of Maryland, Baltimore | Phase 1 |
| Recruiting | Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Pri NCT06607302 | iOMEDICO AG | — |
| Recruiting | Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in A NCT06441747 | Australasian Gastro-Intestinal Trials Group | Phase 2 |
| Recruiting | Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizuma NCT06648057 | CHA University | — |
| Recruiting | Chemotherapy Combined with Immunotherapy and Targeted Therapy in Cholangiocarcinoma NCT06718257 | Second Affiliated Hospital, School of Medicine, Zhejiang University | — |
| Recruiting | Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinom NCT06438822 | West China Hospital | Phase 2 |
| Completed | EchoTip AcuCore Post-Market Clinical Study NCT06358001 | Cook Research Incorporated | — |
| Not Yet Recruiting | Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma NCT06530823 | Eastern Hepatobiliary Surgery Hospital | Phase 2 |
| Not Yet Recruiting | Phase 2 Study: OBI-833/OBI-821 Maintenance for Globo H+ Advanced Biliary Tract Cancer After Gemcitabine/Cispla NCT06490198 | Chang Gung Memorial Hospital | Phase 1 |
| Recruiting | INSPIRE: a Multi-Cancer Early Detection Study NCT06440018 | Singlera Genomics Inc. | — |
| Recruiting | Anti-PD-1/PD-L1 Antibodies Plus Gemcitabine and Cisplatin for Advanced CCA NCT07291063 | Shanghai Zhongshan Hospital | — |
| Recruiting | Agnostic Therapy in Rare Solid Tumors NCT06638931 | Instituto do Cancer do Estado de São Paulo | Phase 2 |
| Recruiting | A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer NCT07224750 | City of Hope Medical Center | — |
| Recruiting | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors NCT06399757 | Apollo Therapeutics Ltd | Phase 1 / Phase 2 |
| Recruiting | Evaluating a Community-Based Behaviour Change Communication Model to Prevent Cholangiocarcinoma in Khon Kaen, NCT05321992 | McMaster University | N/A |
| Enrolling By Invitation | Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT) NCT06963060 | Wei Gong | Phase 2 |
| Enrolling By Invitation | Liquid Biopsy MonitORing Of CholangioCarcinOma for Treatment Response and Prognostic Outcomes (MOROCCO) NCT06474091 | Mayo Clinic | — |
| Not Yet Recruiting | Digital Single-operator Cholangioscopy and Intraductal Ultrasound for Nonicteric Biliary Strictures NCT06369896 | Soonchunhyang University Hospital | — |
| Recruiting | Pemigatinib + Afatinib in Advanced Refractory Solid Tumors NCT06302621 | Massachusetts General Hospital | Phase 1 |
| Recruiting | Targeted Navigation in Hepatocellular Carcinoma (HCC) NCT06260943 | University of Miami | N/A |
| Unknown | Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis NCT06363123 | Beijing Friendship Hospital | — |
| Recruiting | A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers NCT06541652 | Federation Francophone de Cancerologie Digestive | — |
| Recruiting | An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer NCT06342414 | City of Hope Medical Center | — |
| Unknown | Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (M NCT05872867 | Wellmarker Bio | Phase 1 |
| Recruiting | Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers NCT06048133 | Nataliya Uboha | Phase 2 |
| Recruiting | Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio NCT05655949 | Beth Israel Deaconess Medical Center | Phase 2 |
| Completed | Contribution of the EyeMAX™ 11Fr (Micro-Tech) Digital Single-Operator Cholangioscope With a Wide Working Chann NCT06933576 | Clinique Paris-Bercy | — |
| Recruiting | Prognostic Factors for Survival in Patients With Cholangiocarcinoma NCT06369480 | Rigshospitalet, Denmark | — |
| Not Yet Recruiting | Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma NCT06175845 | Universitätsklinikum Hamburg-Eppendorf | N/A |
| Unknown | Evaluation of the Patient's Experience in Medical Studies for Cholangiocarcinoma NCT05694845 | Power Life Sciences Inc. | — |
| Recruiting | A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Re NCT05967182 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Clinical Utility of Selected Circulating Tumor DNA Assays in Patients With Advanced Malignancy NCT06290856 | Oslo University Hospital | — |
| Recruiting | Bile Omics for Diagnosing Indeterminate Biliary Strictures NCT07007832 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | — |
| Unknown | In This Study, a Retrospective Analysis Was Conducted to Explore the Risk Factors for Patients Undergoing Panc NCT06763250 | luokai zhang | — |
| Recruiting | Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma NCT05948475 | TransThera Sciences (Nanjing), Inc. | Phase 3 |
| Unknown | Open Versus Laparoscopic Ablation of Liver Malignancies NCT06304766 | Rigshospitalet, Denmark | N/A |
| Recruiting | Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With NCT06199895 | Liu Huang | Phase 2 |
| Active Not Recruiting | The Expression of CD24 "do-not-eat-me" Signal in Cholangiocarcinoma NCT06707025 | Hadassah Medical Organization | — |
| Recruiting | CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in NCT06037980 | Gruppo Oncologico del Nord-Ovest | Phase 2 / Phase 3 |
| Recruiting | Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malig NCT06126406 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Recruiting | Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors NCT06010862 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Unknown | Prospective Observational Study to Predict the Response of Biliary Tract Tumors to Immunotherapy NCT06048289 | Zhejiang Cancer Hospital | — |
| Recruiting | Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma NCT06341764 | National Cancer Institute, Naples | Phase 2 |
| Active Not Recruiting | A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid NCT05712356 | Lisata Therapeutics, Inc. | Phase 2 |
| Recruiting | Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma NCT05874414 | Genfit | Phase 1 / Phase 2 |
| Completed | Diagnostic Efficacy of EUS-FNA/B Versus ERCP With or Without POCS-TB in Patients With Suspected Hilar Cholangi NCT05993429 | Qilu Hospital of Shandong University | — |
| Withdrawn | Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment NCT05510427 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatop NCT05451043 | AHS Cancer Control Alberta | Phase 2 |
| Active Not Recruiting | Senior Adult Hepatobiliary Prehab Study NCT05921552 | H. Lee Moffitt Cancer Center and Research Institute | N/A |
| Recruiting | Collection of Blood and Tissue Samples From Patients With Primary Liver Cancer. NCT06899854 | Fondazione IRCCS Policlinico San Matteo di Pavia | — |
| Terminated | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors NCT05563272 | Telix Pharmaceuticals (Innovations) Pty Ltd | Phase 2 |
| Active Not Recruiting | Domvanalimab and Zimberelimab in Advanced Liver Cancers NCT05724563 | University of Texas Southwestern Medical Center | Phase 2 |
| Completed | A Study of CDX-585 in Patients With Advanced Malignancies NCT05788484 | Celldex Therapeutics | Phase 1 |
| Recruiting | An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarc NCT05876754 | Servier Affaires Médicales | Phase 3 |
| Completed | Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers NCT05641896 | SOFIE | Phase 2 |
| Completed | Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma (LyMIC) NCT06381648 | City of Hope Medical Center | — |
| Completed | Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Expr NCT05292859 | Alaunos Therapeutics | — |
| Recruiting | [68Ga]Ga-FAPI-46 Positron Emission Tomography (PET) Scan to Improve the Imaging of Pancreatic and Bile Duct Ca NCT05957250 | Amsterdam UMC, location VUmc | N/A |
| Unknown | Study on the Accuracy of Proteomics in Evaluating Lymph Node Metastasis Status in Cholangiocarcinoma Patients NCT05721963 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Unknown | Advanced or Metastatic Cholangiocarcinoma NCT05653817 | First Affiliated Hospital Xi'an Jiaotong University | N/A |
| Terminated | Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC) NCT04989218 | University of Alabama at Birmingham | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or NCT05506943 | Compass Therapeutics | Phase 2 / Phase 3 |
| Unknown | Carlizumab Plus Sovantinib in Second-line Treatment of Advanced or Metastatic Cholangiocarcinoma NCT05697237 | First Affiliated Hospital Xi'an Jiaotong University | N/A |
| Unknown | An Exploratory Clinical Study of Photodynamic Therapy Combined With Sonodynamic Therapy in Cholangiocarcinoma NCT05580328 | Second Affiliated Hospital of Guangzhou Medical University | N/A |
| Unknown | Study on Consistency Evaluation for Drug Sensitivity of Patient-Derived Organoid Model From Cholangiocarcinoma NCT05634694 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Completed | FLUOPANC-trial - Fluorescence-guided Surgery of Pancreatic and Bileduct Tumors Using cRGD-ZW800-1 NCT05518071 | Leiden University Medical Center | Phase 2 |
| Unknown | Screening Single-operator Cholangioscopy for Neoplastic Bile Duct Lesions NCT05600803 | Soonchunhyang University Hospital | — |
| Recruiting | PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metast NCT05286814 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS) NCT06340646 | Washington University School of Medicine | N/A |
| Recruiting | Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers NCT05497531 | University of California, Irvine | N/A |
| Completed | Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma NCT05678218 | Erasmus Medical Center | — |
| Unknown | Bile Duct Drainage After ERCP Failure: EUS-BD vs PTBD NCT05519605 | Radboud University Medical Center | — |
| Completed | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) NCT05461430 | Travera Inc | — |
| Terminated | FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; NCT05432193 | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | Phase 1 |
| Active Not Recruiting | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer NCT05451849 | TCR2 Therapeutics | Phase 1 / Phase 2 |
| Completed | HAIC Combined With Donafenib and Sintilimab for Unresectable ICC NCT05348811 | Zhongda Hospital | Phase 2 |
| Completed | Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients NCT05411133 | Arbele Pty Ltd | Phase 1 |
| Terminated | A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adu NCT05346484 | Imugene Limited | Phase 1 |
| Unknown | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors NCT05311618 | NGM Biopharmaceuticals, Inc | Phase 1 |
| Completed | To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients NCT05253053 | TransThera Sciences (Nanjing), Inc. | Phase 1 / Phase 2 |
| Terminated | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors NCT05194735 | Alaunos Therapeutics | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced o NCT05215574 | NGM Biopharmaceuticals, Inc | Phase 1 |
| Recruiting | Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers NCT04645160 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With NCT04566133 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant NCT02379377 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresect NCT04683939 | BioNTech SE | Phase 1 / Phase 2 |
| Recruiting | GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma NCT05215665 | Tianjin Medical University Cancer Institute and Hospital | N/A |
| Recruiting | Registry for Advanced Endoscopy NCT05187312 | Region Stockholm | — |
| Terminated | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors NCT05194072 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Unknown | Association Between Cell-free Nucleic Acid in Blood, Urine and Microbiome in Stool With Pancreatobiliary Cance NCT05596370 | Seoul National University Hospital | — |
| Unknown | PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholang NCT05207735 | Henan Cancer Hospital | Phase 2 |
| Completed | Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma NCT04919642 | TransThera Sciences (Nanjing), Inc. | Phase 2 |
| Terminated | Milademetan in Advanced/Metastatic Solid Tumors NCT05012397 | Rain Oncology Inc | Phase 2 |
| Completed | Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarci NCT04059562 | Heinrich-Heine University, Duesseldorf | Phase 2 |
| Withdrawn | Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma NCT04895046 | Walid Shaib, MD | Phase 2 |
| Completed | A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumor NCT04853017 | Elicio Therapeutics | Phase 1 |
| Terminated | HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With S NCT05124743 | Alaunos Therapeutics | — |
| Completed | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) NCT05007106 | Merck Sharp & Dohme LLC | Phase 2 |
| Active Not Recruiting | National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer NCT04145141 | National Cancer Institute (NCI) | — |
| Unknown | A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors NCT04801095 | Wellmarker Bio | Phase 1 |
| Terminated | Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer NCT04727541 | AIO-Studien-gGmbH | Phase 2 |
| Active Not Recruiting | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Mal NCT04913337 | NGM Biopharmaceuticals, Inc | Phase 1 / Phase 2 |
| Terminated | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic NCT04644315 | Hoffmann-La Roche | Phase 2 |
| Recruiting | Liver Embolization Approaches for Tumor Management NCT05714124 | IRCCS San Raffaele | — |
| Completed | The Registry of Oncology Outcomes Associated With Testing and Treatment NCT04028479 | Taproot Health | — |
| Withdrawn | Pilot Study on the Evaluation of Irreversible Electroporation Technique in Infiltrating Perihilar Cholangiocar NCT04717687 | Poitiers University Hospital | N/A |
| Terminated | A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma NCT04648319 | American University of Beirut Medical Center | Phase 2 |
| Completed | Biomarker Discovery in Patients With Advanced Biliary Tract Cancer NCT04871321 | CHA University | — |
| Active Not Recruiting | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Express NCT04802876 | SOLTI Breast Cancer Research Group | Phase 2 |
| Unknown | Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors NCT04764084 | Peking University Cancer Hospital & Institute | Phase 1 |
| Completed | Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid NCT04742959 | TransThera Sciences (Nanjing), Inc. | Phase 1 / Phase 2 |
| Recruiting | Deep Liver Phenotyping and Immunology Study NCT04946773 | University of Oxford | — |
| Recruiting | Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients NCT04753996 | Mayo Clinic | — |
| Completed | Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unr NCT04676633 | Sirnaomics | Phase 1 |
| Withdrawn | Neoadjuvant Therapy in Biliary Adenocarcinoma NCT04480190 | Jordan Kharofa | Phase 1 |
| Withdrawn | Implementing Acupuncture and Chinese Herbal Medicine Into Palliative Care NCT04584775 | Medical University of Graz | N/A |
| Unknown | A Study of ICP-192 in Patients With Advanced Solid Tumors NCT04565275 | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Oral Protein Supplements for Nutritional and Quality of Life Improvement After Pancreatic Resection in Elderly NCT06570174 | Yonsei University | N/A |
| Unknown | ENHANCED RECOVERY AFTER BILIARY TRACT SURGERY NCT04633382 | Vitebsk State Medical University | N/A |
| Unknown | A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal NCT04668976 | Benaroya Research Institute | Phase 2 |
| Unknown | A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical NCT04856761 | Fudan University | — |
| Terminated | The PLATON Network NCT05489250 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | — |
| Completed | PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study) NCT04484636 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | N/A |
| Unknown | Hepatobiliary Tumors Tissue Samples Acquisition NCT04445532 | Peking Union Medical College Hospital | — |
| Recruiting | TCF-001 TRACK (Target Rare Cancer Knowledge) Study NCT04504604 | TargetCancer Foundation | N/A |
| Active Not Recruiting | Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations NCT04521686 | Eli Lilly and Company | Phase 1 |
| Terminated | A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant NCT04866836 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Terminated | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors NCT04383210 | Elevation Oncology | Phase 2 |
| Terminated | Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer NCT04304781 | Danielle Kim Turgeon | Phase 1 |
| Active Not Recruiting | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER NCT04430738 | Seagen, a wholly owned subsidiary of Pfizer | Phase 2 |
| Recruiting | Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma NCT04340986 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other NCT04526106 | Elevar Therapeutics | Phase 1 / Phase 2 |
| Enrolling By Invitation | Prospective Evaluation of Biliary Tissue Sampling with ERCP NCT04572711 | Mayo Clinic | — |
| Recruiting | BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours NCT04421820 | Bold Therapeutics, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers NCT04459273 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Recruiting | Liver Cancer Registry Platform NCT04510740 | iOMEDICO AG | — |
| Completed | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies NCT04440943 | Celldex Therapeutics | Phase 1 |
| Completed | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S NCT04430842 | Quadriga Biosciences, Inc. | Phase 1 |
| Terminated | Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer NCT04561453 | University of Washington | — |
| Unknown | the Impact of Early Palliative Care on the Survival of Locally Advanced and / or Metastatic Cholangiocarcinoma NCT04415190 | Central Hospital, Nancy, France | — |
| Active Not Recruiting | Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer NCT04308174 | Asan Medical Center | Phase 2 |
| Completed | Advanced Endoscopy During COVID-19 NCT04385147 | Al-Azhar University | — |
| Completed | Study of Pembrolizumab and Olaparib in Bile Duct Cancer NCT04306367 | Georgetown University | Phase 2 |
| Completed | A Novel Patient Engagement Platform Among Patients With Gastrointestinal Malignancies NCT04316078 | Sheba Medical Center | N/A |
| Completed | A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer NCT04137289 | Boehringer Ingelheim | Phase 1 |
| Completed | Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Includ NCT04256980 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 |
| Completed | Clinical Effect and Safety of PDT and RFA for Unresectable EHCC NCT04301999 | First People's Hospital of Hangzhou | N/A |
| Completed | A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast G NCT04238715 | Eisai Co., Ltd. | Phase 2 |
| Completed | Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations NCT04233567 | Sameek Roychowdhury | Phase 2 |
| Completed | RFA Combined With Chemotherapy for Unresectable Cholangiocarcinoma NCT05028439 | First People's Hospital of Hangzhou | N/A |
| Recruiting | Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors NCT03991832 | University Health Network, Toronto | Phase 2 |
| Terminated | Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma NCT04076761 | Sunnybrook Health Sciences Centre | Phase 2 |
| Completed | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors NCT04157985 | Dan Zandberg | Phase 3 |
| Completed | Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Prod NCT03801915 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC NCT04066491 | EMD Serono Research & Development Institute, Inc. | Phase 2 / Phase 3 |
| Terminated | Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers NCT04077372 | Stanford University | N/A |
| Unknown | Diagnosis, Treatment Status and Prognosis of Cholangiocarcinoma in China: a Multicenter, Two-way, Non-interven NCT04243057 | Beijing Tsinghua Chang Gung Hospital | — |
| Unknown | Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancie NCT04149691 | Celon Pharma SA | Phase 1 |
| Recruiting | Efficacy of Fistulotomy for Biliary Cannulation NCT04037007 | Coordinación de Investigación en Salud, Mexico | N/A |
| Completed | Trastuzumab in HER2-positive Biliary Tract Cancer NCT03613168 | Changhoon Yoo | Phase 2 |
| Terminated | PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile D NCT04099888 | PCI Biotech AS | Phase 2 |
| Unknown | Volumetric Laser Endomicroscopy's (VLE) Diagnostic Accuracy Validation Study: Impact on Clinical Management St NCT03951324 | Innovative Digestive Health Education and Research Inc | — |
| Active Not Recruiting | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors NCT03872947 | Toray Industries, Inc | Phase 1 |
| Completed | Fluorescence QRH-882260 Peptide Imaging in the Bile Duct NCT03438435 | D. Kim Turgeon, MD | Phase 1 |
| Completed | Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors NCT03895970 | Peking Union Medical College Hospital | Phase 2 |
| Active Not Recruiting | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer NCT03907852 | TCR2 Therapeutics | Phase 1 / Phase 2 |
| Unknown | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients NCT03924466 | Universitair Ziekenhuis Brussel | Phase 2 |
| Completed | M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma NCT03833661 | EMD Serono Research & Development Institute, Inc. | Phase 2 |
| Unknown | The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor NCT03896958 | SpeciCare | — |
| Completed | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers NCT03829436 | Tempest Therapeutics | Phase 1 |
| Terminated | Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images NCT03852836 | IHU Strasbourg | N/A |
| Recruiting | Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers NCT03801083 | Udai Kammula | Phase 2 |
| Unknown | Magnetic Compressive Anastomosis for Biliojejunostomy and Pancreaticojejunostomy During Whipple's Procedure NCT03792048 | First Affiliated Hospital Xi'an Jiaotong University | N/A |
| Unknown | Bilioenteric Anastomosis by Magnetic Compressive Technique NCT03774589 | First Affiliated Hospital Xi'an Jiaotong University | N/A |
| Completed | Multiorgan Metabolic Imaging Response Assessment of Abemaciclib NCT03339843 | Jules Bordet Institute | Phase 2 |
| Unknown | Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection NCT03779035 | Tianjin Medical University Cancer Institute and Hospital | Phase 3 |
| Completed | Trial of IRE in Cholangiocarcinoma NCT03769753 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer NCT04642664 | Peking Union Medical College Hospital | Phase 2 |
| Unknown | A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors NCT03734926 | Guangdong Zhongsheng Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal NCT03693807 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors NCT03665285 | NextCure, Inc. | Phase 1 / Phase 2 |
| Unknown | Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma NCT03603834 | Khon Kaen University | Phase 2 |
| Withdrawn | Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, NCT03563352 | University of Southern California | — |
| Completed | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) NCT03207347 | University of Florida | Phase 2 |
| Completed | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Ge NCT03602079 | Klus Pharma Inc. | Phase 1 / Phase 2 |
| Completed | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors NCT03517488 | Xencor, Inc. | Phase 1 |
| Completed | Personal Resilience Empowerment Program Study NCT03644173 | Hackensack Meridian Health | N/A |
| Unknown | Precise Treatment System of Biliary Malignancies Based on Special Disease Database NCT03499782 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | — |
| Completed | Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA NCT03473574 | AIO-Studien-gGmbH | Phase 2 |
| Unknown | Clinical Trial of Autologous Tcm Immunotherapy in ICC NCT03820310 | Newish Technology (Beijing) Co., Ltd. | Phase 2 |
| Recruiting | The Relationship Between Triceps Skinfold and Overall Survival of Pancreas, Bile Duct, Gallbladder Cancer NCT03637569 | Samsung Medical Center | — |
| Completed | A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma NCT03377179 | RedHill Biopharma Limited | Phase 2 |
| Completed | SHR-1210 in Combination With GEMOX in Patients With Advanced BTC NCT03486678 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Completed | MicroRNAs as Bile-based Biomarkers in Pancreaticobiliary Cancers NCT06258824 | Imperial College London | — |
| Recruiting | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry NCT03452774 | Massive Bio, Inc. | — |
| Completed | Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer NCT04656249 | Peking Union Medical College Hospital | Phase 2 |
| Completed | Study on the Quality of Life (QoL) After Liver Surgery NCT05464706 | Humanitas Clinical and Research Center | N/A |
| Completed | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies NCT03329950 | Celldex Therapeutics | Phase 1 |
| Completed | A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable NCT03250273 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Completed | TAS-102 in Treating Advanced Biliary Tract Cancers NCT03278106 | Mayo Clinic | Phase 2 |
| Recruiting | Molecular Epidemiology of Biliary Tree Cancers NCT05179486 | M.D. Anderson Cancer Center | — |
| Terminated | A Trial of Percutaneous vs. Endoscopic Drainage of Suspected Klatskin Tumors NCT03172832 | Medical University of South Carolina | N/A |
| Completed | A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms NCT03219268 | MacroGenics | Phase 1 |
| Terminated | Comparison Bile Duct Brushings, Cholangioscopy-Directed Biopsies and Pediatric Forceps Biopsies in Biliary Str NCT03211169 | Stanford University | N/A |
| Unknown | Gemcitabine + Oxaliplatin +Nab-paclitaxel in Subjects With Advanced Biliary Tract Cancer NCT03943043 | Istituto Clinico Humanitas | Phase 1 / Phase 2 |
| Unknown | Diagnostic Accuracy of ERCP-guided Versus Cholangioscopy-guided Tissue Acquisition in Patients With Indetermin NCT03140007 | Asian Institute of Gastroenterology, India | N/A |
| Completed | Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in NCT03111732 | National Cancer Institute (NCI) | Phase 2 |
| Completed | A Pilot Study to Assess Theragnostically Planned Liver Radiation to Optimize Radiation Therapy NCT03338062 | Indiana University | N/A |
| Unknown | RFA for Malignant Biliary Obstruction NCT03166436 | Institute for Clinical and Experimental Medicine | N/A |
| Terminated | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma a NCT03144661 | Incyte Corporation | Phase 1 |
| Completed | Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma NCT03079427 | Asan Medical Center | Phase 2 |
| Unknown | ncRNAs in Exosomes of Cholangiocarcinoma NCT03102268 | The Second Hospital of Nanjing Medical University | — |
| Completed | A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors NCT02990481 | Toray Industries, Inc | Phase 1 |
| Unknown | Trial of Therapeutic Vaccine in Patients With Cholangiocarcinoma NCT03042182 | Immunitor LLC | Phase 1 / Phase 2 |
| Unknown | Observational Study on Patients With Hepatobiliary Tumors NCT04637048 | Gang Chen, MD | — |
| Completed | A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer NCT03027284 | Eli Lilly and Company | Phase 1 |
| Active Not Recruiting | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors NCT02834013 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangioca NCT02924376 | Incyte Corporation | Phase 2 |
| Recruiting | Biobank for Cholestatic Liver Diseases. NCT03445585 | Mayo Clinic | — |
| Unknown | FGF19 in Obstructive Cholestasis: "Unveil the Signal" NCT05718349 | Nicole Hildebrand | — |
| Completed | Clinico-demographic Profile of the Patient With Pancreaticobiliary Malignancy Undergoing ERCP in a Tertiary Ca NCT06888401 | Kathmandu University School of Medical Sciences | — |
| Terminated | A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors NCT02784795 | Eli Lilly and Company | Phase 1 |
| Unknown | Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy NCT01642875 | Medical University of Warsaw | Phase 4 |
| Unknown | Short-term Starvation vs. Normal Diet Before Chemotherapy of Solid Tumors NCT02607826 | University Hospital Tuebingen | N/A |
| Completed | Enteral Nutrition After Pancreaticoduodenectomy NCT03150615 | Nanjing Medical University | N/A |
| Completed | Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma NCT02631590 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With NCT02821754 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Beacon BNX™ Endoscopic Ultrasound (EUS)-Needle vs SharkCore™ Needle NCT02872831 | Thomas Jefferson University | N/A |
| Completed | Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor T NCT02762721 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | — |
| Completed | Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma NCT02456714 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 2 |
| Recruiting | High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer Tha NCT02757859 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | N/A |
| Completed | Metabolic Syndrome, Bile Acids, Hepatocellular Carcinoma and Cholangiocarcinoma NCT02730611 | Assistance Publique - Hôpitaux de Paris | — |
| Active Not Recruiting | Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis NCT02626312 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Unilateral Stenting Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction NCT02649712 | Xuzhou Central Hospital | N/A |
| Unknown | Biliary Cancer in Italy: a Study on Cholangiocarcinoma cAUSEs and Risk Factors NCT02665494 | Fondazione del Piemonte per l'Oncologia | — |
| Completed | ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract NCT02351765 | The Christie NHS Foundation Trust | Phase 1 |
| Unknown | A Study for Efficacy of Side-by-side Compared to Stent-in-stent Technique in the Endoscopic Management of Mali NCT02659852 | Yonsei University | N/A |
| Completed | DNA Methylation Biomarker for Diagnosis of Cholangiocarcinoma in Patients With Bile Duct Stricture NCT04568512 | Mahidol University | N/A |
| Completed | Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot B NCT02520141 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) NCT02628067 | Merck Sharp & Dohme LLC | Phase 2 |
| Terminated | Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies NCT02638909 | Criterium, Inc. | Phase 2 |
| Completed | Endobiliary Radiofrequency Ablation With S-1 for Unresectable Cholangiocarcinoma NCT02592538 | First People's Hospital of Hangzhou | N/A |
| Active Not Recruiting | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (T NCT02568267 | Hoffmann-La Roche | Phase 2 |
| Completed | ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Syste NCT02609958 | ASLAN Pharmaceuticals | Phase 2 |
| Completed | Metformin And Chloroquine in IDH1/2-mutated Solid Tumors NCT02496741 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 1 / Phase 2 |
| Terminated | RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therap NCT02452970 | EpicentRx, Inc. | Phase 2 |
| Unknown | Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma NCT02548195 | Shanghai Zhongshan Hospital | Phase 3 |
| Completed | Laparotomy, Laparoscopy, da Vinci System NCT07034495 | National Chung Hsing University | — |
| Unknown | In Vitro Models of Liver and Pancreatic Cancer NCT02436564 | Cambridge University Hospitals NHS Foundation Trust | — |
| Completed | Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic NCT02375880 | Leap Therapeutics, Inc. | Phase 1 |
| Terminated | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Ce NCT02479178 | BIND Therapeutics | Phase 2 |
| Unknown | Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma NCT02773485 | Tata Memorial Hospital | Phase 3 |
| Completed | Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Chola NCT02428855 | Massachusetts General Hospital | Phase 2 |
| Recruiting | Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome NCT04792463 | Mohamed Abdel-Rahman | — |
| Terminated | A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinom NCT02374489 | National Health Research Institutes, Taiwan | Phase 2 |
| Terminated | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) NCT02393248 | Incyte Corporation | Phase 1 / Phase 2 |
| Completed | A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer NCT02232633 | Sumitomo Pharma America, Inc. | Phase 2 |